Published in Cancer Weekly, September 16th, 2003
Genentech sued 7 years ago in U.S. District Court alleging that Amgen had infringed on three of its patents while developing Neupogen, a drug used to fight infections in cancer patients undergoing chemotherapy.
Last year, Neupogen sales brought Amgen $1.3 billion.
Under terms of the settlement announced in August, Amgen agreed to make a one-time payment to Genentech, but the company said it would not license any of Genentech's patents. Financial terms were not...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.